Fighting Flu
October 25, 2016
Can bioinformatics point the way towards a universal flu vaccine?
1 min read
October 2016
Welcome to the October issue. Upfront investigates how to make biopharma medicines on demand, GDUFA II, and the EMA’s fight for transparency. In our cover feature, find out what poker can teach us about the biosimilars business. NextGen looks at how to make cell therapies more widely available, and in Business, Alain J. Gilbert argues that orphan medicines are better off alone. We also sit down with Carol Lynch, Global Head Biopharmaceuticals at Sandoz.
The Formulation Complex
October 20, 2016
Conventional formulation tactics do not work for all drugs, but more complex solutions, such as liposomes and microparticles, are giving rise to new opportunities in drug delivery and drug targeting. In this roundtable, experts discuss the trends and challenges in the development and manufacture of complex dosage forms.
1 min read
Better Bioanalytics = Better Bioprocesses
October 20, 2016
A thorough understanding of your process and how it impacts your product’s critical quality attributes is essential for decision-making, development and scale up. Are you up-to-date with new analytical platforms that can give you the edge?
1 min read
Bluff or Serious Biosimilar Bet?
October 20, 2016
The players and chips are ready, and cards are being closely guarded; what can poker teach us about the biosimilars business?
1 min read
Ensuring Orphans Thrive
October 20, 2016
As big pharma looks to snap up an increasing number of successful orphan drug firms, CEOs should be wary because orphans are usually better off alone.
1 min read
Manufacture
Cell & Gene
Facilities & Equipment
Technology & Manufacturing
Regulation & Standards
Bioprocessing
Biopharma
Brave New Factories
October 20, 2016
Cell therapy successes have got the industry talking, but the future of the field now lies in the hands of manufacturing specialists who must develop factories capable of meeting high demands.
1 min read
Biosimilar Champion
October 20, 2016
Sitting Down With... Carol Lynch, Global Head of Biopharmaceuticals, Sandoz, and Chair of the Biosimilar Medicines Group, a sector group of Medicines for Europe.
1 min read
A Universal Shot
October 20, 2016
Development of a universal flu vaccine is not impossible for the industry – we just need bioinformatics to show us the way forward.
1 min read
Swallowability by Design
October 20, 2016
Tablets are still the most common dosage form, but today’s consumers tend to have strong preferences and expect the freedom of choice. Have you considered all of your options?
1 min read
Save Our Insoluble Compounds!
October 20, 2016
Can supersaturation save us from solubility problems? Perhaps, but supersaturation comes with its own challenges.
1 min read
Plague Prevention
October 20, 2016
Bioterrorism concerns prompt the UK government to fund development of a vaccine for plague
1 min read
And the Facility of the Year is…
October 20, 2016
Genentech’s Cell Culture Biologics Drug Substance Plant 2 in Vacaville, California
1 min read
The Fight for Transparency
October 20, 2016
The EMA says “yes” to transparency, but some pharma companies have other ideas
1 min read
Serialization Standardization
October 20, 2016
A consortium of vendors and pharma companies search for a single, serialization standard
1 min read
What’s On The Web?
October 20, 2016
Check in at The Medicine Maker website for webinars, jobs and more
1 min read
Negotiating GDUFA II
October 20, 2016
Are reduced GDUFA fees on the horizon for contract manufacturers?
1 min read
Freeze-Dried Pharma
October 20, 2016
Lyophilized gene networks synthesize biomedicines on-demand – with just a sprinkle of water
1 min read
When Free is Not Good Enough
October 19, 2016
Why has Médecins Sans Frontières rejected an offer of free vaccines from Pfizer?
1 min read
